Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma

Current Opinion in Oncology

Volumn 10, Issue 2, 1998, Pages 170-174

  Rook, Alain H ^a   Yoo, Elisa K ^a   Grossman, Debra J ^a   Kao, David M F ^a   Fox, Floyd E ^a   Niu, Zhutian ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; CELLULAR IMMUNITY; HELPER CELL; HUMAN; IMMUNOPHENOTYPING; PRIORITY JOURNAL; SHORT SURVEY; SKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 0031885746     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199803000-00015     Document Type: Short Survey

References (36)

1. Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 1996, 88:2385-2409. A comprehensive review of the pathophysiology and treatment of CTCL.
2. Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R, Veelken H, Kadin ME, Koh H, Heald P: Detection of clonal T-cell receptor γ gene rearrangements in early mycosis fungoides/Sézary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 1994, 103:34-41.
3. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS: CD8+ tumor-infiltrating lymphocytes influence survival of patients with mycosis fungoides. J Am Acad Dermatol 1995, 32:448-453.
4. Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Cin North Am 1995, 9:1089-1107.
5. Kaplan EH, Rosen ST, Norris DB, Roenigk HH Jr, Saks SR, Bunn PA Jr: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990, 82:208-212.
6. Marolleau JP, Baccard M, Flageul B, Rybojad M, Laroche L, Verola O, Brandely M, Morel P, Gisselbrecht C: High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995, 131:574-579.
7. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989, 321:1784-1790.
8. Vowels BR, Cassin M, Vonderheid E, Rook AH: Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992, 99:90-94.
9. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996, 132:1309-1313. This marvelous analysis is sure to become a classic paper that will guide our intuitive notions regarding therapy and prognosis of limited CTCL.
10. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A: Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988, 19:684-691.
11. Zackheim HS, Epstein EH Jr, Crain WR: Topical carmustine (BCNU) for cutaneous T-cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990, 22:802-810.
12. Herrmann JJ, Roenigk HH Jr, Honigsmann H: Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol/Oncol Clin North Am 1995, 9:1077-1088.
13. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ: Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989, 20:416-428.
14. Rook AH, Lessin SR, Jaworsky C, Singh A, Vowels BR: Immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T-cells. Arch Dermatol 1993, 129:486-489.
15. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf S, Trinchieri G, Lessin SR: Interleukin 12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995, 154:1491-1498.
16. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G: Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood 1996, 88:1383-1389. This study highlights an interesting series of laboratory studies that further confirm that CTCL malignant cell are Th2 cells.
17. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD: Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10. J Invest Dermatol 1996, 107:833-837. This study enhances our understanding of the immunosuppressive cytokines produced by the malignant T cells.
18. Peleman R, Wu J, Rargeas C, Delespesse G: Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med 1989, 170:1751-1756.
19. D'Andrea A, Aste-Amea M, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer cell stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 1993, 178:1041-1048.
20. Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N, Zeffren J: Interferon alfa 2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989, 20:395-407.
21. Knobler RM, Trautinger F, Radaszkiewicz T: Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa 2b and retinoids. J Am Acad Dermatol 1991, 24:247-252.
22. Dreno B, Celorier P, Litoux P: Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 1993, 89(Suppl 1):28-32.
23. Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA Jr, Evans L, Roenigk HH, Rosen ST: Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990, 82:203-207.
24. Gottlieb SL, Wolfe JT, Fox FE, DeNardo B, Macey W, Bromely P, Lessin SR, Rook AH: Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and with recombinant interferon alfa. J Am Acad Dermatol 1996, 35:946-957.
25. Fox FE, Niu Z, Lessin S, Rook AH: Cytokine regulation of the growth of clonal malignant T-cells from patients with Sézary syndrome [abstract]. J Invest Dermatol 1997, 108:552.
26. Gottlieb SL, Fox FE, Cassin M, Fakharzadeh SS, Lessin SR, Rook AH: Interleukin 5 expression by peripheral blood mononuclear cells in Sézary syndrome correlates with peripheral eosinophilia and is suppressed by interferon alfa [abstract]. J Invest Dermatol 1995, 104:683.
27. Platsoucas CD, Fox FE, Oleszak E, Fong K, Nanno M, Ioannides CG, Trotta PP: Regulation of natural killer cytotoxicity by recombinant alpha interferons: augmentation by IFN-alpha 7, an interferon similar to IFN-alpha. J Anticancer Research 1989, 9:849-858.
28. Rook AH, Yoo EK, Wood GS, Elenitsas R, Fox FE, Niu Z, Sherman ML, Kao D, Lessin SR, Vonderheid EC: Interleukin-12 is safe and effective therapy for cutaneous T-cell lymphoma [abstract]. J Invest Dermatol 1998, in press.
29. Wolfe JT, Singh A, Lessin SR, Rook AH: Review of immunomodulation by photopheresis: relevance to neoplasia, autoimmune disease, and allograft rejection. Artif Organs 1994, 18:888-897.
30. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR: Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996, 107:235-242. Initial studies demonstrating that psoralens and ultraviolet light used in photopheresis induce a high level of apoptosis of treated lymphocytes.
31. Vowels BR, Cassin M, Boufal MH, Walsh LJ, Rook AH: Extracorporeal photochemotherapy induces the production of tumor necrosis factor a by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992, 98:686-692.
32. Lim HW, Edelson RL: Photopheresis for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1117-1126.
33. Duvic M, Hester JP, Lemak NA: Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996, 35:573-579. An excellent study indicating a 50% response rate of CTCL patients to photophoresis.
34. Zic JA, Stricklin GP, Greer JP, Kinney MC, Shyr Y, Wilson DC, King LEJ: Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996, 35:935-945. Another well-done study suggesting that some patients with non-erythrodermic CTCL may respond to photophoresis.
35. Floyd FE, Cassin M, Gottlieb S, Fakharzadeh SS, Kubin M, Trinchieri G, Cooper K, Rook AH: Retinoids synergize with IL-2 to increase interferon gamma production by peripheral blood mononuclear cells via induction of IL-12. Ann NY Acad Sci 1996, 795:337-340.
36. Foss FM, Kuzel TM: Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1127-1137.